Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Japanese pharmaceutical firm Eisai's US subsidiary Eisai has entered into a definitive agreement to transfer ownership of its Research Triangle Park (RTP)-based manufacturing facility in North Carolina to Biogen.
Subscribe to our email newsletter
The agreement expands upon the strategic manufacturing alliance entered in December 2012 concerning the North Carolina facility.
As part of the new deal, Eisai will transfer to Biogen the entire North Carolina Plant site, including the oral solid dose (OSD) facility which had been leased by Biogen.
In addition, Biogen will continue to manufacture OSD and parenteral products at the sites for Eisai.
Eisai Global Oncology Manufacturing Unit president and Eisai RTP site general manager Lou Arp said: "The decision to transfer ownership of the RTP campus is part of a global supply chain initiative to optimize Eisai’s logistics strategy in support of our long-term business objectives."
After completion of this transaction, around 100 of the total 180 Eisai employees at the plant will be offered jobs with Biogen, while the remaining will continue with Eisai.
Subject to the satisfaction of all customary provisions generally attached to similar transactions, the deal is expected to be closed in the second quarter.
Following the transfer of manufacturing operations to Biogen, Eisai will continue to base supply chain management services in the Research Triangle Park area.